GBC Blog

In Vitro Diagnostic Market is Expected to Reach $81.3 Billion, Globally, by 2022 – Allied Market Research Aug 31, 2016 PORTLAND, Oregon, August 31, 2016 /PRNewswire/ Original Article According to a new report published by Allied Market Research, titled, “World In Vitro Diagnostics (IVD) Market”, the world in vitro diagnostics (IVD) market is estimated to…

Beleaguered Phage Therapy Trial Presses On     By Kelly Servick   Science 7/24/16 In the face of rising antibiotic resistance, many researchers hope that bacteria-killing viruses known as phages—long available to patients in Eastern Europe—will offer patients in the West with dangerous infections an alternative treatment. A European clinical trial envisioned as the first large-scale…

National Cancer Advisory Board (NCAB) Accepts Blue Ribbon Panel (BRP) September 07, 2016 –  National Cancer Advisory Board (NCAB) at its meeting earlier today accepted the report and recommendations of the Blue Ribbon Panel (BRP) 10 transformative approaches most likely to make a decade’s worth of progress against cancer in five years, a key goal…

Blood Test Developed to Detect Early Alzheimer’s Disease [Original Post] Tue, 06/07/2016 – 8:37pm by Rowan University A research team has developed a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with high accuracy. In…

Curetis has received great results for its diagnostic kit. This new technology to detect sepsis is delivering the same results as standard tests, but it’s faster by 24 hours – critical time to deal with life-threatening infections. http://labiotech.eu/curetis-sepsis-detection-test-24h-faster-treatment/ Based in Stuttgart (Germany), Curetis was the only German biotech to do an IPO in 2015. It did so with a…

USPSTF recognizes Epi proColon as the only blood-based colorectal cancer screening test Convenient and minimal-invasive blood-based testing contributes to USPSTF´s goal of higher screening participation USPSTF guidelines expected to support adoption of Epi proColon by patients, physicians and insurers Berlin (Germany) and Germantown, MD (U.S.A.), June 16, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX,…

Curetis and Axonlab Sign Multi-Market European Distribution Agreement – Axonlab to become exclusive distributor for all Unyvero products in selected Central and Eastern European countries Amsterdam, the Netherlands, Holzgerlingen, Germany, and Baden, Switzerland, June 06, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, and…

You Can’t Stop Seattle – that is the message Delta is sending with the launch of an ad campaign targeting Delta’s growing West Coast hub. http://news.delta.com/you-can-t-stop-delta-seattle-launch-ad-campaign

LabCorp Announces the Launch of the Epi proColon® Test for Colorectal Cancer Screening First FDA-Approved Blood-Based Colorectal Cancer Test Offers Alternative for Patients Non-Compliant with Existing Screening Options [Original post] May 09, 2016 08:45 AM Eastern Daylight Time BURLINGTON, N.C.–(BUSINESS WIRE)–Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced the launch of Epi proColon®,…

IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. (NYSE:Q) announced today that their respective boards of directors approved a definitive merger agreement, pursuant to which the companies will be combined in an all-stock merger of equals transaction. The merged company will be named Quintiles IMS Holdings, Inc. Based on the closing of IMS…